SPIKO, WIREMIND, VATES: nearly 270 million euros announced by French Tech this week

From October 5 to 11, 2026, thirteen French companies from this selection announced nearly 270 million euros in capital financing. Spiko, Wiremind and Vates account for more than half of the amount. Behind these three operations, the investments respond to different needs: scientific validation, industrial capacity or deployment of software already marketed.

The week’s total is driven by companies that are not at the same stage. Spiko finances the expansion of its money market funds. Wiremind and Vates open their capital after years of self-funded development. Rivercell still needs to build some of the experimental infrastructure on which its product will be based, while VoltR and Edonia are preparing to increase their production.

Fundraisers of the week

The total of approximately €270 million adds the amounts invested in capital in this selection, after indicative conversion of the announcements into dollars. For VoltR, it retains €16 million out of a budget of €22 million including €6 million in aid. For Edonia, it retains €12 million of investments out of €15 million of announced financing. It does not constitute an exhaustive account of French levies.

What the composition of the towers reveals

NEA leads Spiko’s Series B. Wiremind welcomes IronWave, Seaya Andromeda and Bpifrance in its first capital opening; Vates brings in IRIS and Bpifrance. These three operations concern companies whose product is already marketed. Investors are funding their ability to expand into more markets, with the recruiting, distribution and product expenses that this expansion entails.

Bpifrance participates in four of the thirteen capital roundsby vehicles meeting distinct needs: Large Venture at Wiremind and Vates, Digital Venture at Rivercell and the SPI 2 industrial fund at VoltR. Edonia also benefits from non-dilutive support.

Specialized funds make these differences more visible. AVP is leading the WhiteLab Genomics tour, devoted in particular to the biological validation of its technologies. HV is funding Rivercell’s seed and construction of its data platform. Norrsken VC leads that of Vocca, while Newfund intervenes in Archeon Medical via HEKA, its fund dedicated to brain health. In the industry, VoltR combines SPI 2 and Decathlon Pulse; Edonia notably brings together SWEN Blue Ocean 2, Asterion Ventures and EIT Food.

Spiko, Wiremind and Vates finance their expansion

Spiko announces $90 million to expand the use of its monetary funds. After a Series A of €18.5 million in 2025, fintech must make its offering accessible in more markets and financial tools. Its competition includes cash products offered by banks and platforms specializing in the placement of corporate cash.

Wiremind, which publishes revenue, capacity and distribution management software for transport and events, is raising €35 million to strengthen its R&D and international presence. The company must convince operators whose pricing and inventory decisions are sometimes based on tools installed for a long time or developed internally.

For Vates, profitable and self-funded since 2016, the €30 million must support both the virtualization platform, the sales teams and the partner network. The re-competition of VMware creates sales opportunities, but an infrastructure migration involves backups, application continuity and the teams who will have to operate the new system. The ability to support these transitions will determine part of Vates’ growth. Its choice to raise while being profitable sheds more light on the trade-offs between self-financing and external capital.

In health, each financing buys different proof

WhiteLab Genomics raises $26M to continue validation in vivo of genomic therapy components designed with AI and develop its commercial partnerships. Computationally designing a promising candidate is a first step; verifying its behavior in a living organism, then establishing its interest in a therapeutic program, constitutes others. The funding is expected to advance these validations as well as the company’s activity in North America, Europe and Asia.

Rivercell raises $25 million in seed money to produce its own experimental data, expand its Paris laboratory and develop models capable of predicting the response of human cells to treatments. Faced with players like Recursion and Insitro, its challenge will be to show that the integration of the laboratory and the software improves a concrete research decision. The value of data, models and experimental capabilities depends in particular on their reuse from one project to another.

Vocca is financing, with $20 million, the deployment of voice agents responsible for processing exchanges between patients and health establishments. Its market covers medical secretarial services, call centers and appointment management software. Archeon Medical, for its part, is raising €7.5 million to continue clinical studies and the deployment of its ventilation assistance device during cardiac arrest.

VoltR and Edonia must convert capital into production

VoltR announces €22 million to industrialize the reconditioning of lithium batteries. The €16 million invested in capital by SPI 2 and Decathlon Pulse are supplemented by €6 million in aid from the Première Usine program. The company wants to significantly increase its capacity in Verrières-en-Anjou. Its activity must be distinguished from recycling: it seeks to put cells back into use, which requires characterizing them, assembling them and guaranteeing the quality of the batteries produced as volumes increase.

Edonia announces €15 million in financing, including €12 million in investments, to open a unit dedicated to its ingredient derived from microalgae. The company targets catering and food manufacturers in Europe and internationally. Scaling up will have to establish that it can provide regular volumes, adapted to the formulation and price constraints of its customers. The financing of a production tool here responds to a different logic than that of a software platform: expenses precede the increase in volumes sold.

Business software seeks a place in daily operations

With more than $10 million raised from investors led by Partech, Netsec wants to bring together IT and cybersecurity in a subscription billed per employee. The company competes against established outsourcing providers, security tool providers and its clients’ internal teams. As it centralizes interventions, the quality of its incident response and clarity of responsibilities become critical. These criteria are included in our guide to purchasing and deploying these cybersecurity services.

Cleavr raises €8 million to automate invoice tracking until payment. Its product must fit between accounting software, financial teams and client contacts, particularly when an invoice is the subject of a dispute. Verso raises around €5.4 million to accelerate consumer studies. The young company competes against established institutes and platforms like Outset, GetWhy or Listen Labs; the drop in the cost of producing studies also makes the question of their price and the quality of the results more pressing.

Fleuret AI closes this list with €4 million in pre-seed to develop agents capable of automating part of intrusion tests. Faced with specialized firms and security tools already used by companies, it will have to demonstrate the relevance of the flaws detected, the reproducibility of the tests and the place left for human expertise. RAISE Ventures leads the round, including Auriga Cyber ​​Ventures, Wind and Better Angle.

One week of capital, several deadlines

The nearly €270 million in this selection finances stages whose results will not be measured at the same pace. For Spiko, Wiremind and Vates, the question is about expansion and customer loyalty. For WhiteLab, Rivercell and Archeon, the next proofs will first be scientific or clinical. For VoltR and Edonia, they will come off the production lines.